Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Forecast & Price Target

Compare

8 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SUNPHARMA Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Sun

Pharmaceutical Industries Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SUNPHARMA Stock 12 Month Forecast

Average Price Target

₹2,005.60

▲(11.78% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Sun Pharmaceutical Industries Limited in the last 3 months. The average price target is ₹2,005.60 with a high forecast of ₹2,180.00 and a low forecast of ₹1,935.00. The average price target represents a 11.78% change from the last price of ₹1,794.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1562":"₹1,562","2181":"₹2,181","1716.75":"₹1,716.8","1871.5":"₹1,871.5","2026.25":"₹2,026.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2180,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹2.18K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2005.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹2.01K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1935,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.94K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1562,1716.75,1871.5,2026.25,2181],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1689.85,1727.553846153846,1765.2576923076922,1802.9615384615383,1840.6653846153845,1878.3692307692306,1916.0730769230768,1953.7769230769231,1991.480769230769,2029.1846153846154,2066.8884615384613,2104.5923076923077,2142.2961538461536,{"y":2180,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1689.85,1714.1384615384613,1738.426923076923,1762.7153846153844,1787.003846153846,1811.2923076923075,1835.5807692307692,1859.8692307692306,1884.1576923076923,1908.4461538461537,1932.7346153846154,1957.0230769230768,1981.3115384615385,{"y":2005.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1689.85,1708.7076923076922,1727.5653846153846,1746.423076923077,1765.2807692307692,1784.1384615384616,1802.996153846154,1821.853846153846,1840.7115384615383,1859.5692307692307,1878.426923076923,1897.2846153846153,1916.1423076923077,{"y":1935,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1901.65,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1901.65,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1791.48,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1872.32,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1726.98,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1588.67,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1691.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1824.2,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1661.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1629.05,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1563.35,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1636.15,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1689.85,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹2,180

Average Price Target₹2,006

Lowest Price Target₹1,935

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Abdulkader Puranwala

ICICI Securities

₹1,965

Buy

9.51%

Upside

Reiterated

11/06/25

ICICI Securities Remains a Buy on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Damayanti Kerai

HSBC

₹1,850→₹1,935

Buy

7.84%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Vivek Agrawal CFA

Citi

₹2,180

Buy

21.50%

Upside

Reiterated

09/30/25

Citi Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Kunal Dhamesha

Macquarie

₹2,000

Buy

11.46%

Upside

Reiterated

09/29/25

Macquarie Remains a Buy on Sun Pharmaceutical Industries Limited (SUNPHARMA)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR2,000.00 price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN).

Binay Singh

Morgan Stanley

₹1,960→₹1,948

Buy

8.57%

Upside

Reiterated

09/24/25

Morgan Stanley Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Saion Mukherjee

Nomura

₹1,970→₹1,910

Hold

6.45%

Upside

Reiterated

08/04/25

Sun Pharmaceutical Industries Limited (SUNPHARMA) Gets a Hold from NomuraNomura/Instinet analyst Saion Mukherjee lowered the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,910.00 (from INR1,970.00) while maintaining a Neutral rating.

Bansi Desai

J.P. Morgan

₹2,030→₹1,970

Buy

9.79%

Upside

Reiterated

08/01/25

Sun Pharmaceutical Industries Limited (SUNPHARMA) Gets a Buy from J.P. MorganJPMorgan analyst Bansi Desai lowered the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,970.00 (from INR2,030.00) while maintaining a Overweight rating.

Alankar Garude

Kotak Mahindra

₹1,900→₹1,875

Buy

4.50%

Upside

Reiterated

05/23/25

Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Lowered to INR1,875 at KotakKotak analyst Alankar Garude lowered the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,875.00 (from INR1,900.00) while maintaining a Add (2) rating.

Shyam Srinivasan

Goldman Sachs

₹1,475→₹1,500

Sell

-16.40%

Downside

Reiterated

04/18/25

Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Raised to INR1,500 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan raised the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,500.00 (from INR1,475.00) while maintaining a Sell rating.

Neha Manpuria

Bank of America Securities

₹1,955→₹1,940

Hold

8.12%

Upside

Reiterated

01/31/25

Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Lowered to INR1,940 at BofA SecuritiesBofA Securities analyst Neha Manpuria lowered the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,940.00 (from INR1,955.00) while maintaining a Neutral rating.

Alok Dalal

Jefferies

₹2,260→₹2,265

Buy

26.23%

Upside

Reiterated

01/31/25

Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Raised to INR2,265 at JefferiesJefferies analyst Alok Dalal raised the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR2,265.00 (from INR2,260.00) while maintaining a Buy rating.

Kunal Lakhan

CLSA

₹1,820→₹1,880

Hold

4.78%

Upside

Reiterated

01/23/25

Sun Pharmaceutical Industries Ltd. (SUNP:IN) PT Raised to INR1,880 at CLSACLSA analyst Kunal Lakhan raised the price target on Sun Pharmaceutical Industries Ltd. (SUNP:IN) to INR1,880.00 (from INR1,820.00) while maintaining a Hold (3) rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Abdulkader Puranwala

ICICI Securities

₹1,965

Buy

9.51%

Upside

Reiterated

11/06/25

ICICI Securities Remains a Buy on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Damayanti Kerai

HSBC

₹1,850→₹1,935

Buy

7.84%

Upside

Reiterated

10/14/25

HSBC Keeps Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Vivek Agrawal CFA

Citi

₹2,180

Buy

21.50%

Upside

Reiterated

09/30/25

Citi Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Kunal Dhamesha

Macquarie

₹2,000

Buy

11.46%

Upside

Reiterated

09/29/25

Binay Singh

Morgan Stanley

₹1,960→₹1,948

Buy

8.57%

Upside

Reiterated

09/24/25

Morgan Stanley Reaffirms Their Buy Rating on Sun Pharmaceutical Industries Limited (SUNPHARMA)

Saion Mukherjee

Nomura

₹1,970→₹1,910

Hold

6.45%

Upside

Reiterated

08/04/25

Bansi Desai

J.P. Morgan

₹2,030→₹1,970

Buy

9.79%

Upside

Reiterated

08/01/25

Alankar Garude

Kotak Mahindra

₹1,900→₹1,875

Buy

4.50%

Upside

Reiterated

05/23/25

Shyam Srinivasan

Goldman Sachs

₹1,475→₹1,500

Sell

-16.40%

Downside

Reiterated

04/18/25

Neha Manpuria

Bank of America Securities

₹1,955→₹1,940

Hold

8.12%

Upside

Reiterated

01/31/25

Alok Dalal

Jefferies

₹2,260→₹2,265

Buy

26.23%

Upside

Reiterated

01/31/25

Kunal Lakhan

CLSA

₹1,820→₹1,880

Hold

4.78%

Upside

Reiterated

01/23/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sun Pharmaceutical Industries Limited

1 Month

xxx

Success Rate

2/3 ratings generated profit

Average Return

-1.90%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of -1.90% per trade.

3 Months

xxx

Success Rate

3/4 ratings generated profit

Average Return

+2.38%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +2.38% per trade.

1 Year

Bansi DesaiJ.P. Morgan

Success Rate

4/4 ratings generated profit

Average Return

+6.95%

reiterated a buy rating 5 months ago

Copying Bansi Desai's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +6.95% per trade.

2 Years

xxx

Success Rate

4/4 ratings generated profit

Average Return

+6.95%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +6.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SUNPHARMA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SUNPHARMA has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. SUNPHARMA average Analyst price target in the past 3 months is 2,005.60.

Each month's total comprises the sum of three months' worth of ratings.

SUNPHARMA Financial Forecast

SUNPHARMA Earnings Forecast

Next quarter’s earnings estimate for SUNPHARMA is ₹12.77 with a range of ₹12.10 to ₹13.78. The previous quarter’s EPS was ₹13.00. SUNPHARMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SUNPHARMA has Performed in-line its overall industry.

SUNPHARMA Sales Forecast

Next quarter’s sales forecast for SUNPHARMA is ₹146.10B with a range of ₹144.84B to ₹147.60B. The previous quarter’s sales results were ₹144.78B. SUNPHARMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SUNPHARMA has Performed in-line its overall industry.

SUNPHARMA Stock Forecast FAQ

What is IN:SUNPHARMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Sun Pharmaceutical Industries Limited’s 12-month average price target is 2,005.60.

What is IN:SUNPHARMA’s upside potential, based on the analysts’ average price target?

Sun Pharmaceutical Industries Limited has 11.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Sun Pharmaceutical Industries Limited a Buy, Sell or Hold?

Sun Pharmaceutical Industries Limited has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Sun Pharmaceutical Industries Limited’s share price target?

The average share price target for Sun Pharmaceutical Industries Limited is 2,005.60. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹2,180.00 ,and the lowest forecast is ₹1,935.00. The average share price target represents 11.78% Increase from the current price of ₹1,794.3.

What do analysts say about Sun Pharmaceutical Industries Limited?

Sun Pharmaceutical Industries Limited’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Sun Pharmaceutical Industries Limited?

To buy shares of IN:SUNPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Sun Pharmaceutical Industries Limited (SUNPHARMA) Stock Forecast & Price Target

SUNPHARMA Analyst Ratings

SUNPHARMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sun Pharmaceutical Industries Limited

SUNPHARMA Analyst Recommendation Trends

SUNPHARMA Financial Forecast

SUNPHARMA Earnings Forecast

SUNPHARMA Sales Forecast

SUNPHARMA Stock Forecast FAQ

Detailed List of Analyst Forecasts